At the DFS interim analysis, IMpower010( NCT02486718 ) showed significantly improved disease-free survival ( DFS ) with adjuvant atezolizumab vs. best supportive care( BSC ) following platinum-based chemotherapy in the PD-L1-positive and all stage II-IIIA non-small cell lung cancer( NSCLC ) populations. Here are the findings of the initial interim analysis of overall survival ( OS ).